BRCA Saliva screen




Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

https://tinyurl.com/y2f44mch

 

         As discussed during the recent education session, the excess capacity for genetic testing post Covid is a resource that will be used. 

         This article refers to a proposed new saliva test for BRCA positive mutations. A commercial company; (Genetic Technologies) has developed it, the testing aimed at the US market, will be done in Fitzroy, Melbourne.

         The expected positive rate is 0.5%, the company suggest a negative result will provide comfort. However, with the normal incidence of breast and ovarian cancer being much greater, this may be cold comfort. Apparently FDA approval is not required for Consumer Initiated Testing. Currently the legality in Australia is in doubt. 






Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

How common is complete clearance?

Image
Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities https://tinyurl.com/4698cc7c In the treatment of ovarian cancer, the most important determinant of survival is the effectiveness of the initial surgical procedure. The aim is complete clearance and for about 80% of women no residual cancer can be detected either by CT scan or plasma CA 125 levels. Despite this only about 20% of women will have be en cured sugge sting that residual cancer is present despite evidence to the contrary. This study shows the true rate of minimal residual disease (MRD) , by measuring c i rculatin g tumour DNA (CT DNA) , and by repeat “second look” laparoscopy after completion of surgery and chemo. Findings from the study showed that of 95 patients thought to have had a complete clearance at initial surgery almost half had MRD with abnormal CT DNA or second look laparoscopy. These women had ...
Read more

It’s not just your genotype

Image
Exploring causal relationships between brain imaging-derived phenotypes and ovarian cancer risk: a bidirectional Mendelian randomization https://tinyurl.com/yhfkpwyb One of the perplexing aspects of ovarian cancer is why there is individual variation between those who do have cancer and those who don’t . It would be expected that women with high risk due to genetic mutation such as BR CA2 would all eventually succumb to breast or ovarian cancer. However, many (about 2 0%) , do not. This study suggests that brain structure and function may be part of the reason this is so. Magnetic Resonance Imaging (MRI) is able in a non-invasive way to identify different brain shapes and anatomy . Using data from the UK Biobank study it has bee n possible to identify 12 distinct varieties of brain anatomy which have an influence on ovarian cancer. Further investigation suggested distinct areas of brain cortex variation, with the right medial cortex being protective , and the right pre-cen...
Read more